M. Kulyk & Associates LLC Increases Stock Position in Becton, Dickinson and Company $BDX

M. Kulyk & Associates LLC increased its position in Becton, Dickinson and Company (NYSE:BDX) by 8.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 41,713 shares of the medical instruments supplier’s stock after buying an additional 3,120 shares during the quarter. Becton, Dickinson and Company comprises about 1.6% of M. Kulyk & Associates LLC’s investment portfolio, making the stock its 22nd biggest position. M. Kulyk & Associates LLC’s holdings in Becton, Dickinson and Company were worth $7,807,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BDX. Gilbert & Cook Inc. increased its stake in Becton, Dickinson and Company by 2.0% during the second quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock worth $490,000 after acquiring an additional 56 shares during the last quarter. Mendel Money Management increased its position in Becton, Dickinson and Company by 2.6% during the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock worth $388,000 after purchasing an additional 58 shares in the last quarter. Focus Financial Network Inc. raised its holdings in Becton, Dickinson and Company by 2.2% in the third quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock valued at $504,000 after buying an additional 58 shares during the period. Phillips Wealth Planners LLC lifted its position in Becton, Dickinson and Company by 2.7% during the third quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock valued at $430,000 after buying an additional 58 shares in the last quarter. Finally, CX Institutional lifted its position in Becton, Dickinson and Company by 3.6% during the third quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock valued at $324,000 after buying an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares of the company’s stock, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 3,416 shares of company stock valued at $675,557. Insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BDX. Stifel Nicolaus raised their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Royal Bank Of Canada set a $172.00 price target on Becton, Dickinson and Company in a report on Tuesday, February 10th. Citigroup reduced their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Wells Fargo & Company lowered their target price on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 10th. Finally, Jefferies Financial Group dropped their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $195.46.

Becton, Dickinson and Company Stock Down 0.7%

Shares of Becton, Dickinson and Company stock opened at $184.16 on Tuesday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $186.30. The company has a market capitalization of $52.44 billion, a PE ratio of 30.04, a P/E/G ratio of 13.44 and a beta of 0.25. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The business has a 50-day moving average of $197.01 and a 200-day moving average of $192.46.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the prior year, the business posted $3.43 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has authorized a stock buyback plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 68.52%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.